Results from a 24-week study comparing GSK’s Anoro Ellipta umeclidinium /vilanterol DPI to Boehringer Ingelheim’s Spiriva Handihaler tiotropium DPI published in Respiratory Medicine show statistically greater improvement in trough FEV1 and weighted mean FEV1 0 – 6 hour post dose for UMEC/VI compared to tiotropium. The study involved a total of 905 COPD patients.
Patients experienced a similar frequency of adverse events for both inhalers, with a 44% incidence of on-treatment adverse events for those treated with Anoro Ellipta and 42% for Spiriva Handihaler. The incidence of serious adverse events in both groups was 4%.
GSK Senior VP and Head, Global Respiratory Franchise, Darrell Baker commented, “We are pleased to announce the publication of these important data comparing Anoro Ellipta with tiotropium. These results support the lung function benefit of Anoro Ellipta in the treatment of appropriate patients with COPD. We hope the publication will inform physicians as they consider which treatment option is best to meet their individual patient’s needs.”
Anoro Ellipta was approved in the US in Deceber 2013 and in Europe in May 2014.
Read the GSK press release.
